BRIEF published on 12/19/2025 at 12:05, 3 months 3 days ago Biotest AG annonce l'approbation par la FDA du Fesilty™ de Grifols Biotest AG Marché Américain Approbation De La FDA Grifols Thérapie Au Fibrinogène
BRIEF published on 12/19/2025 at 12:05, 3 months 3 days ago Biotest AG Announces FDA Approval of Grifols' Fesilty™ FDA Approval Biotest AG U.S. Market Grifols Fibrinogen Therapy
PRESS RELEASE published on 12/19/2025 at 12:00, 3 months 3 days ago Biotest announces US FDA approval of Grifols’ Fesilty™ (fibrinogen, human-chmt) Biotest AG announces US FDA approval of Grifols’ Fesilty™ (fibrinogen, human-chmt) for acute bleeding episodes in patients with fibrinogen deficiency Biotest AG Fibrinogen Grifols US FDA Approval Fesilty
BRIEF published on 11/13/2025 at 10:12, 4 months 9 days ago Biotest obtient l'autorisation de mise sur le marché de Prufibry® en Allemagne Biotest AG Essais Cliniques Marché Allemand Approbation Prufibry® Déficit En Fibrinogène
BRIEF published on 11/13/2025 at 10:12, 4 months 9 days ago Biotest Obtains Approval for Prufibry® in Germany Clinical Trials Biotest AG German Market Prufibry® Approval Fibrinogen Deficiency
PRESS RELEASE published on 11/13/2025 at 10:07, 4 months 9 days ago Biotest obtains approval for new human fibrinogen Prufibry® in Germany Biotest AG obtains approval in Germany for new human fibrinogen Prufibry®, expanding intensive care and coagulation factor portfolio with a life-saving therapy for congenital and acquired fibrinogen deficiency Germany Biotest AG Approval Human Fibrinogen Prufibry
BRIEF published on 11/07/2025 at 15:24, 4 months 15 days ago Biotest AG convoque une assemblée générale extraordinaire à la demande de Grifols Assemblée Générale Extraordinaire Grifols SA Société En Commandite Par Actions Biotest AG Changement De Forme Juridique
BRIEF published on 11/07/2025 at 15:24, 4 months 15 days ago Biotest AG Schedules Extraordinary General Meeting at Grifols' Request Grifols S.A. Extraordinary General Meeting Biotest AG Legal Form Change Partnership Limited By Shares
PRESS RELEASE published on 11/07/2025 at 15:19, 4 months 15 days ago Biotest AG: Extraordinary general meeting convened again at the request of Grifols S.A. Biotest AG convenes an extraordinary general meeting at the request of Grifols S.A. to discuss changing its legal form to a partnership limited by shares (KGaA) on 17 December 2025 Grifols S.A. Extraordinary General Meeting Biotest AG Legal Form Change Partnership Limited By Shares
BRIEF published on 10/23/2025 at 13:21, 4 months 30 days ago Biotest AG Cancels Extraordinary General Meeting Grifols S.A. Extraordinary General Meeting Legal Form Change Corporate Restructuring Biotest AG News
Published on 03/23/2026 at 02:00, 4 hours 59 minutes ago FutureGen Industries Announces Open Market Investments
Published on 03/20/2026 at 13:30, 2 days 17 hours ago Unusual Machines Announces Pricing of Approximately $150 Million Public Offering of Common Stock
Published on 03/23/2026 at 06:47, 11 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Appendix 3C daily buy back notice
Published on 03/23/2026 at 03:35, 3 hours 23 minutes ago Deye 2026 Frankfurt Distributor & Partner Summit Concludes Successfully
Published on 03/22/2026 at 12:23, 18 hours 36 minutes ago Borussia Dortmund and Sebastian Kehl are ending their collaboration with immediate effect
Published on 03/20/2026 at 22:45, 2 days 8 hours ago Investor Alert: Berger Montague (Canada) PC represents investors that purchased shares of Super Micro Computer, Inc. listed on the CBOE Canada and elsewhere
Published on 03/20/2026 at 19:00, 2 days 11 hours ago AXA - Conditions for availability or consultation of information relating to AXA’s Shareholders’ Meeting of April 30, 2026
Published on 03/20/2026 at 19:00, 2 days 11 hours ago AXA - Modalités de mise à disposition ou de consultation des informations relatives à l’Assemblée Générale du 30 avril 2026
Published on 03/20/2026 at 18:15, 2 days 12 hours ago Publication of AXA’s 2025 Universal Registration Document
Published on 03/20/2026 at 18:15, 2 days 12 hours ago Mise à disposition du Document d’Enregistrement Universel 2025 d’AXA
